These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37477856)

  • 1. Systematic Review of Neovascular Age-Related Macular Degeneration Disease Activity Criteria Use to Shorten, Maintain or Extend Treatment Intervals with Anti-VEGF in Clinical Trials: Implications for Clinical Practice.
    Patel PJ; Villavicencio P; Hanumunthadu D
    Ophthalmol Ther; 2023 Oct; 12(5):2323-2346. PubMed ID: 37477856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
    Khanani AM; Guymer RH; Basu K; Boston H; Heier JS; Korobelnik JF; Kotecha A; Lin H; Silverman D; Swaminathan B; Willis JR; Yoon YH; Quezada-Ruiz C
    Ophthalmol Sci; 2021 Dec; 1(4):100076. PubMed ID: 36246941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.
    Regillo C; Singh R; Hamilton R; Gedif K; Best C; Koh A; Holz FG
    Ophthalmologica; 2022; 245(5):403-412. PubMed ID: 35468601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
    Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
    Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cataract surgery in neovascular AMD: impact on visual acuity and disease activity.
    Tang HY; Rosén M; Granstam E
    BMC Ophthalmol; 2023 Jun; 23(1):276. PubMed ID: 37328798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
    Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
    Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
    Jaffe GJ; Martin DF; Toth CA; Daniel E; Maguire MG; Ying GS; Grunwald JE; Huang J;
    Ophthalmology; 2013 Sep; 120(9):1860-70. PubMed ID: 23642377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypothetical Switch of Anti-Vascular Endothelial Growth Factor in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis.
    Tuerksever C; Somfai GM; Oesch S; Machewitz T; Hasler PW; Zweifel S
    Ophthalmol Ther; 2022 Apr; 11(2):613-627. PubMed ID: 35066801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.
    Patil NS; Mihalache A; Dhoot AS; Popovic MM; Muni RH; Kertes PJ
    JAMA Ophthalmol; 2022 Jun; 140(6):611-622. PubMed ID: 35551359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.
    Wykoff CC; Clark WL; Nielsen JS; Brill JV; Greene LS; Heggen CL
    J Manag Care Spec Pharm; 2018 Feb; 24(2-a Suppl):S3-S15. PubMed ID: 29383980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-related macular degeneration: using morphological predictors to modify current treatment protocols.
    Ashraf M; Souka A; Adelman RA
    Acta Ophthalmol; 2018 Mar; 96(2):120-133. PubMed ID: 29130626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining response to anti-VEGF therapies in neovascular AMD.
    Amoaku WM; Chakravarthy U; Gale R; Gavin M; Ghanchi F; Gibson J; Harding S; Johnston RL; Kelly SP; Lotery A; Mahmood S; Menon G; Sivaprasad S; Talks J; Tufail A; Yang Y
    Eye (Lond); 2015 Jun; 29(6):721-31. PubMed ID: 25882328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials.
    Singer M; Khanani AM; Wolf A; Flores R; Chhablani J; B G; Clemens A; Gedif K; Liu X; Mulyukov Z; Querques G
    Ophthalmologica; 2022; 245(4):315-322. PubMed ID: 35344964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy for neovascular age-related macular degeneration.
    Evans JR; Igwe C; Jackson TL; Chong V
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004004. PubMed ID: 32844399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes.
    Spooner K; Fraser-Bell S; Hong T; Phan L; Wong JG; Chang A
    Ophthalmol Retina; 2021 Jun; 5(6):511-518. PubMed ID: 33007523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis.
    Ye L; Jiaqi Z; Jianchao W; Zhaohui F; Liang Y; Xiaohui Z
    Ther Adv Chronic Dis; 2020; 11():2040622320953349. PubMed ID: 32953000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
    Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
    Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.